Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fimasartan - Boryung

Drug Profile

Fimasartan - Boryung

Alternative Names: Arakhor; BR-A-657; BR-A-657-K; Kanarb

Latest Information Update: 02 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boryung
  • Developer Boryung; Covance; R-Pharm
  • Class Antihypertensives; Pyrimidinones; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Essential hypertension; Hypertension

Highest Development Phases

  • Marketed Essential hypertension; Hypertension
  • Phase III Kidney disorders
  • No development reported Diabetic nephropathies; Myocardial infarction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Nov 2017 Boryung Pharmaceutical completes a phase I trial for Hypertension (In volunteers) in South Korea (NCT03250052)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top